Hostname: page-component-848d4c4894-x24gv Total loading time: 0 Render date: 2024-05-15T11:30:34.029Z Has data issue: false hasContentIssue false
  • English
  • Français

Mupirocin Resistance: Clinical and Molecular Epidemiology

Published online by Cambridge University Press:  02 January 2015

Suzanne F. Bradley ,
Mary A. Ramsey ,
Teresa M. Morton  and
Carol A. Kauffman
Suzanne F. Bradley*
Affiliation:
Divisions Of Infectious Diseases and Geriatric Medicine, Department of Internal Medicine, University of Michigan Medical Center, Department of Veterans Affairs, Ann Arbor, Michigan Department of Biology, Eastern Michigan University, Ypsilanti, Michigan
Mary A. Ramsey
Affiliation:
Divisions Of Infectious Diseases and Geriatric Medicine, Department of Internal Medicine, University of Michigan Medical Center, Department of Veterans Affairs, Ann Arbor, Michigan Department of Biology, Eastern Michigan University, Ypsilanti, Michigan
Teresa M. Morton
Affiliation:
Divisions Of Infectious Diseases and Geriatric Medicine, Department of Internal Medicine, University of Michigan Medical Center, Department of Veterans Affairs, Ann Arbor, Michigan Department of Biology, Eastern Michigan University, Ypsilanti, Michigan
Carol A. Kauffman
Affiliation:
Divisions Of Infectious Diseases and Geriatric Medicine, Department of Internal Medicine, University of Michigan Medical Center, Department of Veterans Affairs, Ann Arbor, Michigan Department of Biology, Eastern Michigan University, Ypsilanti, Michigan
*
GRECC IIG, VA Medical Center, 2215 Fuller Road, Ann Arbor, MI 48105
Get access Rights & Permissions [Opens in a new window]

Abstract

The antistaphylococcal activity of topical mupirocin has made it an attractive agent for the treatment of asymptomatic colonization with Staphylococcus aureus. Increasing use has been associated with the emergence of mupirocin resistance in staphyloccoci, and failure of therapy has been associated with the isolation of strains exhibiting high-level resistance (MIC >500 μg/mL). Fortunately, low-level mupirocin resistance (MIC <100 μg/mL) occurs most commanly. Because a novel gene encoding for mupirocin resistance resides in both low-level and high-level resistant strains, the emergence of low-level mupirocin resistance may not be as epidemiologically insignificant as previously thought.

Type
Molecular Hospital Epidemiology
Information
Infection Control & Hospital Epidemiology , Volume 16 , Issue 6 , June 1995 , pp. 354 - 358
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1995

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Casewell, MW, Hill, RLR. Mupirocin (‘pseudomonic acid’)--a promising new topical antimicrobial agent. J Antimicrob Chemother 1987;19:1–5.Google Scholar
2.Bradley, SEEffectiveness of mupirocin in the control of methicillin-resistant Staphylococcus aureus. Infections in Medicine 1993;10:2533.Google Scholar
3.Casewell, MW, Hill, RLR. In-vitro activity of mupirocin (‘pseudomonicacid’) against clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 1985;15:523–531.Google Scholar
4.Fuchs, PC. Jones, RN, Barry, AL. Interpretive criteria for disk diffusion susceptibility testing of mupirocin. a topical antibiotic. J Clin Microbial 1990;28:608–609.Google Scholar
5.Scully, BE, Briones, F, Gu, J-W, Neu, HC. Mupirocin treatment of nasal staphylococcal colonization. Arch Intern Med 1992;152:353–356.Google Scholar
6.Doebbling, DN, Breneman, DL, Neu, HC, et al.Elimination of Staphylococcus aureus nasal carriage in health care workers: analysis of six clinical trials with calcium mupirocin ointment. Clin Infect Dis 1993;17:466–474.Google Scholar
7.Doebbling, BN. Nasal and hand carriage of Staphylococcus aureus in healthcare workers. J Chemother 1994;6:11S17S.Google Scholar
8.Sutherland, R, Boon, RJ, Griffin, KE, Masters, PJ, Slomcombe, B, White, AR. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use. Antimicrob Agents Chemother 1985;27:495–498.Google Scholar
9.Maple, PAC. Hamilton-Miller, JMT, Brumfitt, W. Comparison of the in-vitro activities of the topical antimicrobials azelaic acid, nitrofurazone, silver sulfadiazine, and mupirocin against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 1992;29:661–668.Google Scholar
10.Baird, D. Coia, J. Mupirocin-resistant Staphylococcus aureus. Lancet 1987;2:387–388.Google Scholar
11.Kavi, J, Andrews, JM, Wise, R. Mupirocin-resistant Staphylococcus aureus. Lancet 1987;2:1472.Google Scholar
12.Smith, MD, Sanghrajka, M, Lock, S. Mupirocin-resistant Staphylococcus aureus. Lancet 1987;2:1472–1473.Google Scholar
13.Davies, EA, Emmerson, AM, Hogg, GM, Patterson, MF, Shields, MD. An outbreak of infection with a methicillin-resistant Staphylococcus aureus in a special care baby unit: value of topical mupirocin and of traditional methods of infection control. J Hosp Infect 1987;10:120–128.Google Scholar
14.Goldfarb, J, Crenshaw, D, O'Horo, J. Lemon, E, Blumer, JL. Randomized clinical trial of topical mupirocin versus oral erythromycin for impetigo. Antimicrob Agents Chemother 1988;32:1780–1783.Google Scholar
15.Lever, R, Hadley, K. Downey, D, Mackie, R. Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy. Br J Dermatol 1988;119:189–198.Google Scholar
16.Menzies, RE, Cornere, BM, MacCulloch, D. Adaptation of methicillin-resistant Staphylococcus aureus during antibiotic therapy. J Antimicrob Chemother 1989;23:923–927.Google Scholar
17.Van Der Auwera, P: Godard, C, Denis, C, De Maeyer, S, VanHoof, R. In vitro activities of new antimicrobial agents against multiresistant Staphylococcus aureus isolated from septicemic patients during a Belgian National Survey from 1983 to 1985. Antimicrob Agents Chemother 1990:34:2260–2262.Google Scholar
18.Wise, R, Johnson, J. Mupirocin resistance. Lancet 1991;338:578.Google Scholar
19.Wise, R. Mupirocin resistance. Lancet 1992;339:56.Google Scholar
20.Redhead, RJ, Lamb, YJ, Rowsell, RB. The efficacy of calcium mupirocin in the eradication of nasal Staphylococcus aureus carriage. Br J Clin Pharmaco1 1991;45:252–254.Google Scholar
21.Kauffman, CA, Terpenning, MS, He, X, Zarins, LTRamsey, MA, Jorgenson, KA. Attempts to eradicate methicillin-resistant Staphylococcus aureus from a long-term care facility with the use of mupirocin ointment. Am J Med 1993;94:371–378.Google Scholar
22.Smith, GE, Kennedy, CTC. Staphylococcus aureus resistant to mupirocin. J Antimicrob Chemother 1988;21:141.Google Scholar
23.Rahman, M, Noble, WC, Cookson, B. Transmissible mupirocin resistance in Staphylococcus aureus. Epidemiol Infect 1989;102:261–270.Google Scholar
24.Cookson, BD. Lacey, RIV, Noble, WC, Reeves, DS, Wise, R. Redhead, RJ. Mupirocin-resistant Staphylococcus aureus. Lancet 1990;335:1095.Google Scholar
25.Layton, MC, Perez, M, Heald, P, Patterson, JE. An outbreak of mupirocin-resistant Staphylococcus aureus on a dermatology ward associated with an environmental reservoir. Infect Control Hosp Epidemiol 1993;14:369–375.Google Scholar
26.Layton, MC, Patterson, JE. Mupirocin resistance among consecutive isolates of oxacillin-resistant and borderline oxacillin-resistant Staphylococcus aureus at university hospital. Antimicrob Agents Chemother 1994;38:1664–1667.Google Scholar
27.Rahman, M, Noble, WC, Cookson, B. Mupirocin-resistant Staphylococcus aureus. Lancet 1987;2:387.Google Scholar
28.Boelaert, JR. Staphylococcus aureus infection in hemodialysis patients. Mupirocin as a topical strategy against nasal carriage: a review. J Chemother 1994;6:19S–24S.Google Scholar
29.Connolly, S, Noble, WC, Phillips, I. Mupirocin resistance in coagulase-negative staphylococci. J Med Microbial 1993;39:450–453.Google Scholar
30.Naguib, MH, Naguib, MT, Floumoy, DJ. Mupirocin resistance in methicillin-resistant Staphylococcus aureus from a veterans hospital. Chemotherapy 1993;39:400–404.Google Scholar
31.Neu, HC. The use of mupirocin in controlling methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol 1990;11:11.Google Scholar
32.Rahman, M, Connolly, S, Noble, WC, Cookson, B, Phillips, I. Diversity of staphylococci exhibiting high-level resistance to mupirocin. J Med Microbiol 1990;33:97–100.Google Scholar
33.Capobianco, JO, Doran, CC, Goldman, RC. Mechanisms of mupirocin transport into sensitive and resistant bacteria. Antimicrob Agents Chemother 1989;33:156–163.Google Scholar
34.Cookson, B. Failure of mupirocin-resistant staphylococci to inactivate mupirocin. Eur J Clin Microbiol Infect Dis 1989;8:1038–1040.Google Scholar
35.Farmer, TH, Gilbart, J, Elson, SW. Biochemical basis of mupirocin resistance in strains of Staphylococcus aureus. J Antimicrob Chemother 1992;30:587–596.Google Scholar
36.Dyke, KGH, Curnock, SF: Golding, M, Noble, WC. Cloning of the gene conferring resistance to mupirocin in Staphylococcus aureus. FEMS Microbiol Lett 1991;77:195–198.Google Scholar
37.Gilbart, J, Perry, CR, Slocombe, B. High-level mupirocin resistance in Staphylococcus aureus evidence for two distinct isoleucyl-tRNA synthetases. Antimicrob Agents Chemother 1993;37:32–38.Google Scholar
38.Hodgson, JE. Curnock, SPDyke, KGH, Morris, R, Sylvester, DR, Gross, MS. Molecular characterization of the gene encoding high-level mupiricin resistance in Staphylococcus aureus J2870. Antimicrob Agents Chemother 1994;38:1205–1208.Google Scholar
39.Noble, WC, Rahman, M, Cookson, B, Phillips, I. Transferable mupirocin-resistance. J Antimicrob Chemother 1988;22:771–776.Google Scholar
40.Janssen, DA, Zarins, LT, Schaberg, DR. Bradley, SETerpenning, MS, Kauffman, CA. Detection and characterization of mupirocin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1993;37:2003–2006.Google Scholar
41.Rahman, M, Noble, WC, Dyke, KGH. Probes for the study of mupirocin resistance in staphylococci. J Med Microbial 1993;39:446–449.Google Scholar
42.Morton, T, Patterson, J, Schaberg, D, Archer, G. Appearance of a mupirocin resistance gene on a staphylococcal conjugative plasmid: a model for IS-mediated recombination. Taken from Interscience Conference on Antimicrobial Agents and Chemotherapy; 1993. Abstract.Google Scholar
43.Ramsey, MA, Zarins, LTBradley, SE: Kauffman, CA, Morton, TM. Identification of the mupirocin resistance gene on the staphylococcal chromosome: evidence to support IS-mediated recombination. Taken from American Society for Microbiology; 1994. Abstract.Google Scholar
44.Slocombe, B, Perry, C. The antimicrobial activity of mupirocin-an update on resistance. J Hosp Infect 1991;19B:19–25.Google Scholar
45.Cookson, BD. Mupirocin resistance in staphylococci. J Antimicrob Chemother 1990;25:497–503.Google Scholar